Orion Pharma Collaborates with Criceto for Aporon to Treat OFF Episodes in Parkinson’s Disease
Shots:
- Orion & Criceto have entered into an exclusive license agreement to develop & commercialize Aporon for the treatment of OFF episodes in pts with Parkinson’s disease
- As per the deal, Orion will obtain global exclusive license of Aporon excl. the US & Canada in exchange for upfront payments, reimbursements for development costs & sales-based royalties
- Aporon is an apomorphine oromucosal spray which is being evaluated in a Criceto-led P-III trial as the 1L treatment of OFF episodes in Parkinson’s disease
Ref: GlobeNewswire | Image: Orion & Criceto
Related News:- Marinus Pharmaceuticals Highlights the P-III (RAISE) Study Data of Ganaxolone to Treat Refractory Status Epilepticus (RSE) at NCS 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
